Serum CEACAM1 level was elevated in OS patients compared to those with benign bone tumors and controls (455.2 ± 179.9 vs 287.4 ± 103.2, 260.8 ± 109.7 pg/ml, respectively; Fig 1). This evidence concerns the gene CEACAM1 and bone benign neoplasm.